<p>Lyell Immunopharma, Inc.（纳斯达克代码：LYEL - 获取免费报告）在周五的交易中股价下跌了 4.6%。该股票最低交易价为 29.71 美元，最后交易价为 29.35 美元。在交易中，共成交了 12,364 股，较平均交易量 74,330 股下降了 83%。该股票此前收盘价为 30.78 美元。</p>
<p>获取 <strong>Lyell Immunopharma</strong> 的提醒：</p>
<h2>华尔街分析师预测增长</h2>
<p>几位股票研究分析师对 LYEL 股票发表了评论。HC Wainwright 将 Lyell Immunopharma 的股票评级从 “中性” 上调至 “买入”，并在 12 月 9 日的研究报告中将其目标价从 20.00 美元提高至 45.00 美元。Weiss Ratings 在 10 月 8 日的报告中重申了对 Lyell Immunopharma 股票的 “卖出（d-）” 评级。一位分析师给予该股票 “买入” 评级，另一位则给予 “卖出” 评级。根据 MarketBeat.com 的数据，Lyell Immunopharma 目前的平均评级为 “持有”，共识目标价为 45.00 美元。</p>
<p><strong>查看我们关于 Lyell Immunopharma 的最新研究报告</strong></p>
<h2>Lyell Immunopharma 股价下跌 10.8%</h2>
<p>该公司的 50 日移动平均线为 24.65 美元，200 日移动平均线为 16.53 美元。该公司的市值为 5.8314 亿美元，市盈率为-1.19，贝塔值为-0.14。</p>
<p>Lyell Immunopharma（纳斯达克代码：LYEL - 获取免费报告）最近于 11 月 12 日发布了季度财报。该公司报告每股收益（EPS）为-2.13 美元，超出分析师共识预期的-2.81 美元，超出幅度为 0.68 美元。该公司在本季度的收入为 0.02 百万美元，而分析师预期为 0.01 百万美元。Lyell Immunopharma 的股本回报率为-96.68%，净利润率为-794,292.69%。研究分析师预计 Lyell Immunopharma, Inc.在本年度将发布-0.78 的每股收益。</p>
<h2>对 Lyell Immunopharma 的对冲基金看法</h2>
<p>大型投资者最近调整了对该股票的持有。Millennium Management LLC 在第三季度将其在 Lyell Immunopharma 的持股增加了 140.0%。Millennium Management LLC 目前拥有 125,361 股该公司的股票，价值 2,036,000 美元，此前在该期间内又购买了 73,132 股。Foresite Capital Management V LLC 在第三季度将其在 Lyell Immunopharma 的持股增加了 17.3%。Foresite Capital Management V LLC 目前拥有 477,078 股该公司的股票，价值 7,748,000 美元，此前在该期间内又收购了 70,426 股。ARCH Venture Management LLC 在第三季度将其在 Lyell Immunopharma 的持股增加了 51.5%。ARCH Venture Management LLC 目前拥有 2,759,072 股该公司的股票，价值 44,807,000 美元，此前在上个季度又收购了 938,438 股。Two Sigma Investments LP 在第三季度将其在 Lyell Immunopharma 的持股增加了 107.0%。Two Sigma Investments LP 目前拥有 20,827 股该公司的股票，价值 338,000 美元，此前在该期间内又收购了 10,768 股。最后，Takeda Pharmaceutical Co. Ltd.在第三季度将其在 Lyell Immunopharma 的持股增加了 33.3%。Takeda Pharmaceutical Co. Ltd.目前拥有 54,887 股该公司的股票，价值 891,000 美元，此前在上个季度又购买了 13,722 股。66.05% 的股票由机构投资者持有。</p>
<h2>Lyell Immunopharma 公司简介</h2>
<p>（获取免费报告）</p>
<p>Lyell Immunopharma 是一家临床阶段的生物技术公司，专注于开发针对癌症的下一代 T 细胞疗法。该公司利用一个结合了细胞疗法、基因编辑和分子发现的专有平台，旨在克服治疗实体肿瘤的关键障碍。该公司的方法集中在工程化 T 细胞，以增强其持久性、功能性和对免疫抑制肿瘤微环境的抵抗力。</p>
<p>该公司的产品线包括多个自体 T 细胞项目，旨在针对黑色素瘤、卵巢癌和胰腺癌等实体恶性肿瘤中的肿瘤相关抗原。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 Lyell Immunopharma</li>
<li>在 2026 年 1 月 1 日之前购买这只 2 美元的黄金股票</li>
<li>警报：在 2026 年 1 月之前抛售这五只股票！</li>
<li>中国的轰动性揭露</li>
<li>请勿删除，立即阅读</li>
<li>BNZI 发布创纪录的第三季度收入 – 看看推动因素是什么。</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Lyell Immunopharma 吗？</h2>
<p>在考虑 Lyell Immunopharma 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Lyell Immunopharma 并不在名单上。</p>
<p>虽然 Lyell Immunopharma 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

LYEL

<p>Lyell Immunopharma（纳斯达克代码：LYEL）股价下跌 4.6%，至 29.35 美元，交易量较平均水平下降 83%。分析师意见不一，HC Wainwright 将该股票评级上调至 “买入”，并将目标价提高至 45 美元，而 Weiss Ratings 则维持 “卖出” 评级。该公司报告的季度每股收益为（2.13 美元），超出预期，但股本回报率为负的 96.68%。机构投资者持有 66.05% 的股份，公司专注于开发用于癌症的 T 细胞疗法</p>

<p>Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) shares fell 4.6% during trading on Friday . The stock traded as low as $29.71 and last traded at $29.35. 12,364 shares changed hands during trading, a decline of 83% from the average session volume of 74,330 shares. The stock had previously closed at $30.78.</p>
<div class="lb-trans"><p>Lyell Immunopharma, Inc.（纳斯达克代码：LYEL - 获取免费报告）在周五的交易中股价下跌了 4.6%。该股票最低交易价为 29.71 美元，最后交易价为 29.35 美元。在交易中，共成交了 12,364 股，较平均交易量 74,330 股下降了 83%。该股票此前收盘价为 30.78 美元。</p>
</div><p>Get <strong>Lyell Immunopharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Lyell Immunopharma</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several equities research analysts have commented on LYEL shares. HC Wainwright raised shares of Lyell Immunopharma from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and boosted their price target for the stock from $20.00 to $45.00 in a research report on Tuesday, December 9th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Lyell Immunopharma in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Lyell Immunopharma presently has an average rating of &#34;Hold&#34; and a consensus target price of $45.00.</p>
<div class="lb-trans"><p>几位股票研究分析师对 LYEL 股票发表了评论。HC Wainwright 将 Lyell Immunopharma 的股票评级从 “中性” 上调至 “买入”，并在 12 月 9 日的研究报告中将其目标价从 20.00 美元提高至 45.00 美元。Weiss Ratings 在 10 月 8 日的报告中重申了对 Lyell Immunopharma 股票的 “卖出（d-）” 评级。一位分析师给予该股票 “买入” 评级，另一位则给予 “卖出” 评级。根据 MarketBeat.com 的数据，Lyell Immunopharma 目前的平均评级为 “持有”，共识目标价为 45.00 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Lyell Immunopharma</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Lyell Immunopharma 的最新研究报告</strong></p>
</div><h2>Lyell Immunopharma Stock Down 10.8%</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 股价下跌 10.8%</h2>
</div><p>The business has a fifty day moving average of $24.65 and a 200 day moving average of $16.53. The firm has a market cap of $583.14 million, a P/E ratio of -1.19 and a beta of -0.14.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为 24.65 美元，200 日移动平均线为 16.53 美元。该公司的市值为 5.8314 亿美元，市盈率为-1.19，贝塔值为-0.14。</p>
</div><p>Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($2.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.81) by $0.68. The company had revenue of $0.02 million during the quarter, compared to analysts' expectations of $0.01 million. Lyell Immunopharma had a negative return on equity of 96.68% and a negative net margin of 794,292.69%. Research analysts expect that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.</p>
<div class="lb-trans"><p>Lyell Immunopharma（纳斯达克代码：LYEL - 获取免费报告）最近于 11 月 12 日发布了季度财报。该公司报告每股收益（EPS）为-2.13 美元，超出分析师共识预期的-2.81 美元，超出幅度为 0.68 美元。该公司在本季度的收入为 0.02 百万美元，而分析师预期为 0.01 百万美元。Lyell Immunopharma 的股本回报率为-96.68%，净利润率为-794,292.69%。研究分析师预计 Lyell Immunopharma, Inc.在本年度将发布-0.78 的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Lyell Immunopharma</h2>
<div class="lb-trans"><h2>对 Lyell Immunopharma 的对冲基金看法</h2>
</div><p>Large investors have recently modified their holdings of the stock. Millennium Management LLC boosted its holdings in shares of Lyell Immunopharma by 140.0% during the 3rd quarter. Millennium Management LLC now owns 125,361 shares of the company's stock worth $2,036,000 after buying an additional 73,132 shares during the period. Foresite Capital Management V LLC raised its holdings in Lyell Immunopharma by 17.3% in the 3rd quarter. Foresite Capital Management V LLC now owns 477,078 shares of the company's stock valued at $7,748,000 after acquiring an additional 70,426 shares during the period. ARCH Venture Management LLC lifted its position in Lyell Immunopharma by 51.5% during the third quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company's stock worth $44,807,000 after acquiring an additional 938,438 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of Lyell Immunopharma by 107.0% during the third quarter. Two Sigma Investments LP now owns 20,827 shares of the company's stock worth $338,000 after acquiring an additional 10,768 shares during the period. Finally, Takeda Pharmaceutical Co. Ltd. grew its position in shares of Lyell Immunopharma by 33.3% in the third quarter. Takeda Pharmaceutical Co. Ltd. now owns 54,887 shares of the company's stock valued at $891,000 after purchasing an additional 13,722 shares during the last quarter. 66.05% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>大型投资者最近调整了对该股票的持有。Millennium Management LLC 在第三季度将其在 Lyell Immunopharma 的持股增加了 140.0%。Millennium Management LLC 目前拥有 125,361 股该公司的股票，价值 2,036,000 美元，此前在该期间内又购买了 73,132 股。Foresite Capital Management V LLC 在第三季度将其在 Lyell Immunopharma 的持股增加了 17.3%。Foresite Capital Management V LLC 目前拥有 477,078 股该公司的股票，价值 7,748,000 美元，此前在该期间内又收购了 70,426 股。ARCH Venture Management LLC 在第三季度将其在 Lyell Immunopharma 的持股增加了 51.5%。ARCH Venture Management LLC 目前拥有 2,759,072 股该公司的股票，价值 44,807,000 美元，此前在上个季度又收购了 938,438 股。Two Sigma Investments LP 在第三季度将其在 Lyell Immunopharma 的持股增加了 107.0%。Two Sigma Investments LP 目前拥有 20,827 股该公司的股票，价值 338,000 美元，此前在该期间内又收购了 10,768 股。最后，Takeda Pharmaceutical Co. Ltd.在第三季度将其在 Lyell Immunopharma 的持股增加了 33.3%。Takeda Pharmaceutical Co. Ltd.目前拥有 54,887 股该公司的股票，价值 891,000 美元，此前在上个季度又购买了 13,722 股。66.05% 的股票由机构投资者持有。</p>
</div><h2>Lyell Immunopharma Company Profile</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company's approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.</p>
<div class="lb-trans"><p>Lyell Immunopharma 是一家临床阶段的生物技术公司，专注于开发针对癌症的下一代 T 细胞疗法。该公司利用一个结合了细胞疗法、基因编辑和分子发现的专有平台，旨在克服治疗实体肿瘤的关键障碍。该公司的方法集中在工程化 T 细胞，以增强其持久性、功能性和对免疫抑制肿瘤微环境的抵抗力。</p>
</div><p>The company's pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.</p>
<div class="lb-trans"><p>该公司的产品线包括多个自体 T 细胞项目，旨在针对黑色素瘤、卵巢癌和胰腺癌等实体恶性肿瘤中的肿瘤相关抗原。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Lyell Immunopharma</li>
<li>Buy this $2 Gold Stock Before January 1, 2026</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>Bombshell Exposé on China Strikes</li>
<li>Do not delete, read immediately</li>
<li>BNZI Posts Record Q3 Revenue – See What’s Driving It.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Lyell Immunopharma</li>
<li>在 2026 年 1 月 1 日之前购买这只 2 美元的黄金股票</li>
<li>警报：在 2026 年 1 月之前抛售这五只股票！</li>
<li>中国的轰动性揭露</li>
<li>请勿删除，立即阅读</li>
<li>BNZI 发布创纪录的第三季度收入 – 看看推动因素是什么。</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Lyell Immunopharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Lyell Immunopharma 吗？</h2>
</div><p>Before you consider Lyell Immunopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Lyell Immunopharma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Lyell Immunopharma 并不在名单上。</p>
</div><p>While Lyell Immunopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Lyell Immunopharma 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Lyell Immunopharma (NASDAQ:LYEL) 股价下跌 4.6% - 以下是原因